GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FIT Biotech Oy (OHEL:FITBIO) » Definitions » NonCurrent Deferred Income Tax

FIT Biotech Oy (OHEL:FITBIO) NonCurrent Deferred Income Tax : €0.00 Mil (As of Jun. 2018)


View and export this data going back to 2015. Start your Free Trial

What is FIT Biotech Oy NonCurrent Deferred Income Tax?

Non-Current Deferred Income Tax represents the non-current portion of deferred income taxes, which is the difference in income recognition between tax laws and the accounting methods.

FIT Biotech Oy's non-current deferred income tax for the quarter that ended in Jun. 2018 was €0.00 Mil.

FIT Biotech Oy NonCurrent Deferred Income Tax Historical Data

The historical data trend for FIT Biotech Oy's NonCurrent Deferred Income Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FIT Biotech Oy NonCurrent Deferred Income Tax Chart

FIT Biotech Oy Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
NonCurrent Deferred Income Tax
- - - - -

FIT Biotech Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18
NonCurrent Deferred Income Tax Get a 7-Day Free Trial Premium Member Only - - - - -

FIT Biotech Oy NonCurrent Deferred Income Tax Related Terms

Thank you for viewing the detailed overview of FIT Biotech Oy's NonCurrent Deferred Income Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


FIT Biotech Oy Business Description

Industry
Traded in Other Exchanges
N/A
Address
Biokatu 12, Tampere, FIN, FI-33520
FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.

FIT Biotech Oy Headlines

No Headlines